ClinicalTrials.Veeva

Menu

Efficacy Comparison of Warfarin Versus Rivaroxaban CVT

I

Isfahan University of Medical Sciences

Status and phase

Unknown
Phase 2
Phase 1

Conditions

Cerebral Venous Thrombosis

Treatments

Drug: Warfarin
Drug: Rivaroxaban

Study type

Interventional

Funder types

Other

Identifiers

NCT03747081
Isfahan Stroke Unit

Details and patient eligibility

About

With regard to Cerebral Venous Thrombosis (CVT) importance as a life threatening disease, specific care is necessary, Known anti-coagulants have limitations.Vitamin K antagonists such as Warfarin, require laboratory monitoring and exact administration starting and maintenance dose. although Rivaroxaban(selective and direct Xa factor antagonist ) has no monitoring and no drug interaction. This study aim to focus on efficacy of Warfarin versus Rivaroxaban.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

IInclusion Criteria:

  • Patients of both gender
  • Age 18 years and higher
  • proven CVT on neuro imaging ( MRI-MRV)

Exclusion Criteria:

  • Patients suffering from renal failure(GFR<30) Patients
  • Patients with contraindications for oral anticoagulation
  • Patient who having pregnancy
  • Uncooperative patient for completing the course of treatment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

50 participants in 2 patient groups

Rivoroxaban
Experimental group
Description:
Patients would be administered Enoxaparine (60 mg/SC/BID)in first day, after dicontinuing Enoxaparin in second day, Rivoroxaban 20 mg per day will use. .it would be given once a day.The total duration of Rivoroxaban would be 3 months.
Treatment:
Drug: Rivaroxaban
warfarin
Active Comparator group
Description:
Patients would be administered Warfarin with overlap of Enoxaparine utill INR adjust to 2-3 then enoxaparine will disconstinue.it would be given once a day.The total duration of Warfarin would be 3 months
Treatment:
Drug: Warfarin

Trial contacts and locations

1

Loading...

Central trial contact

Mohammad Javad Farajpour Khanaposhtani, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems